Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … It is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease.

  2. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. … It is being developed by Vitae Pharmaceuticals.

  3. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

  4. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. … Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying … It possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.

    Categories: MATE 1 Inhibitors, P-glycoprotein inhibitors
  6. Drug

    OP-145

    go.drugbank.com/drugs/DB05672
    Experimental

    OP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.

    Synonyms: (4S)-4-(((2S)-2-((2-(((2S,3S)-2-ACETAMIDO-3-METHYL-PENTANOYL)AMINO)ACETYL)AMINO)-6-AMINO-HEXANOYL)AMINO)-5-(((1S)-2-(((1S)-5-AMINO-1-(((1S)-1-(((1S,2S)-1-(((1S)-1-(((1S)-1-(((1S)-1-(((1S,2S)-1-(((1S)-5, -AMINO-1-(((1S)-1-(((1S)-1-BENZYL-2-(((1S)-1-(((1S)-1
  7. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  8. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. … It is being developed by Fibrex Medical Inc.

  9. Drug

    1-Ethyl-Pyrrolidine-2,5-Dione

    go.drugbank.com/drugs/DB01902
    Experimental

    Synonyms: 1-Ethyl-Pyrrolidine-2,5-DioneCategories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Sinefungin

    go.drugbank.com/drugs/DB01910
    Experimental

    Sinefungin is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.

    Synonyms: (2S,5S)-2,5-diamino-6-[(2R,3S,R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]hexanoic acid, 6,9-Diamino-1-(6-amino-9H-purin-9-yl)-1,5,6,7,8,9-hexadeoxy-beta-D-ribo-decofuranuronic acidCategories: Heterocyclic Compounds, 2-Ring